* Clink on the link to download
- Adulterated Herbal products on the market
- Analysis for Nitrosamine impurities in drugs
- Caution against stockpiling and irrational use of medicine
- Certification of premises used to supply restricted drugs within institutions conducting clinical trials
- Circular No 040 Pharmacovigilance requirements for Remdesivir products under emergency importation
- CIRCULAR NO 031
- Circular no. 032- Presence of a potentially genotoxic impurity, N-nitrosodimethylamine (NDMA) in Ranitidine
- Circular no.2 – suspension of registration of products from the drug register
- Circular no.23 -suspension of registration of products from the Drug register
- Circular on falsified chloroquine products circulating in Africa
- Circular on falsified Human Immunodeficiency Virus (HIV) Uni-Gold test kits
- Circular on Importation of personal protective equipment
- Circular on Importation, Exportation & sale of Chloroquine & Hydroxychloroquine
- Clarification on Hydrochlorothiazide
- Communication circular on Clinical Trial new format for CT certificates
- Detection of Impurity in the Active Pharmaceutical Ingredient (API) valsartan manufactured by Zhejiang Huahai Pharmaceuticals, Linhai, China
- Disabling and potentially permanent side effects associated with quinolone and fluoroquinolone antibiotics
- Emergency use of Remdesivir in the context of the Covid-19 Pandemic
- Extension of the deadline for submission of CTD dossiers for renewal of registration
- Furosemide injection manufactured by Grand pharmaceutical (china) co., ltd; batch number 180120
- Guidance on legal requirements for importation of drugs into Uganda
- Guidance on the attributes of a valid proforma invoice when importing unregistered drugs
- Implementation of Good Distribution Practices (GDP)
- Increased risk of non-melanoma skin cancer associated with HCTZ
- Institutional Pharmacies amended
- Labelling requirements for surgical sutures
- Licensing of Drug shops for 2019
- Licensing of pharmacies in private hospitals and medical centers
- Licensing of pharmacies in private hospitals and medical centers
- National Drug Authority statement on conduct of Clinical Trials during the COVID-19 lockdown
- National Drug Policy & Authority (amendment) regulations 2021
- New registration numbers (NDAMIS numbers) for Herbal medicines
- New registration numbers (NDAMIS numbers) for Veterinary Drugs
- Prescription records
- Provisions for emergency importation of Remdesivir in the context of the COVID-19 Pandemic
- Public Warning : Adulterated & substandard herbal products on the market – Embaluka hardcore drink & Megapower
- Re-registration of pharmaceutical products
- Records of prescriptions
- Records of wholesale pharmacies
- Regulation of chemicals scheduled under the third schedule (Group II) of the National Drug Policy and Authority Act (Cap 2016)
- Requirement for a Pharmacovigilance system for licensed persons in Uganda
- Response to suggested amendments to the Guidelines on submitting periodic safety update report and any other reports that may be relevant to determine the safety, efficacy and quality of a drug
- Retention of products for financial year 2018 / 2019
- Retention of products for the financial year 2020 / 2021
- Risk of crystalization of Mannitol 20% iv solution
